Feedback Share Discussion Threads

[lr2] 02/9/2019 21:33

OK Sonie,

Re your post #2543.

In the placing document it states, "In the UK, across NHS hospital, community and primary care settings, there are approximately 150,000 doctors in total and over 320,000 nurses and midwives."

So a potential 470,000 users at first glance. However take out GP's and nursing staff working outside hospitals, say 25%, then practical UK market for Bleepa is down to around 352,500 and many of them work at multiple hospitals.

I'd estimate true market is around 275,000 individuals.

15% take up would be 41,250.

41,250 individuals at £10 a month is a yearly revenue stream of £4,950,000.

Round it up to £5 million for ease of use.

I expect that to be a maximum yearly U.K. income for Bleepa for the first couple of years whilst other software packages already in use run out their contracts.

[georgesorearse] 02/9/2019 21:31

Sonie01

I spoke to Tom Oakley last week and asked him how the NHS hospitals and trusts were set up - the answer was a bit surprising in that some have singular autonomy and others are in a collective, the NHS Expo therefore has a number of people it can target as first movers, big and small, pricing matrix depends upon size of user etc so nothing set in stone there are economies of scale available to larger users.

In the U.K we also have a few different private health care companies that use the same Doctors and specialists from the NHS, seamless transition for their own back office systems.

He further advised the Bleepa office and future processing guys were buzzing with Bleepa and its forthcoming launch, he said when in the office you can feel the excitement.

Texrad - was set up for lungs and is currently under review, will be announced after the launch of Bleepa, I asked Tom outright if it can scan Lungs surely it can scan for other organs and he side stepped it, I went back and asked again later on and he said wait for the review but it has great potential.

I invested here for Bleeps,if I'd found it earlier I would have taken this for Texrad - great technology, I think that Texrad will be expanded and built into Bleepa to make it the number one choice for the NHS to take onboard.

Texrad is in use already, India seems to be the foreign health service targeted for Bleepa expansion if my texrad bolt on idea is correct - English is one of their two major nationwide languages so it makes sense.

Six months review think this will bang - very reassuring to read those two TR1's today... massive holdings both of them..

[sonie01] 02/9/2019 21:22

Peeps let's try and focus on the current issues and between us ALL let's try and determine any value in the current offering. Many minds together are far effective than one mind. I agree that the past has to be taken into consideration, there's potential here, let's evaluate between us all of its real and give it a value

[lr2] 02/9/2019 21:16

Re post #2539.

No, nothing to do with Trump. I was told FDA approval for TexRAD was not a top priority and work on it would not start before June of this year. Bleepa subsequently surfaced as a reason why that might have been the case. Maybe the priority will alter after Bleepa launch.

As for IQAI, as I have said on numerous occasions, how does StoneChecker get FDA approval when TexRAD is the core software in this product and TexRAD doesn't have FDA approval (or even, I suspect, a completed U.S. Patent)? You and HH believe what the IQAI board tell you and yet over one year later you are still waiting. Odd isn't it?

Want a bet on what gets FDA approval first? TexRAD Lung or Stone Checker.

[sonie01] 02/9/2019 21:06

Thanks Pete. What is the USP of our offering? What sets it apart?

[hazl] 02/9/2019 20:50

Do the lth's think that the delay in FDA approval, for not just here but IQAI,too,could be anything to do with the America first mantra, that Trump is trying to promote?
I read that that could be the case, because seemingly, management over on IQAI have paid for expert -help in getting FDA approval but it still hasn't happened as far as I know.

[petekand] 02/9/2019 20:41

They certainly do stack up, there's competitors out there but we are led to believe we have a far superior offering. Hence, we can only come to further conclusions once we have seen the product and heard from the experts.

[ducatiman] 02/9/2019 20:33

Sonie, I would like to think that with the large amount of cash they have acquired in the last two years that all bases will have been covered!

[sonie01] 02/9/2019 20:25

Based on the fundamentals they seem to stack up, just hope the management see it. Go for the blanket contract if possible. Any news on potential threats?

[ducatiman] 02/9/2019 20:21

Sonie your figures for the UK market are very appealing! ;-)

[petekand] 02/9/2019 20:11

I think we can only do this once we have more meat on the bones, i.e. watch the launch, press comments, finer details about the app and any deals signed, etc.

[sonie01] 02/9/2019 20:05

Same here Pete I invested for Texrad too. It's important to identify the potential external threats to Bleepa so we can assume a realist price for the future

[petekand] 02/9/2019 20:03

Agreed.
Thomas Charlton has just effectively given the company another £400k in the placing on top of his already monster holding and that isn't small pocket money either! Well, it may be for him!
I still continue to believe Texrad will play an even more important role for FDBK than Bleepa. It simply has to as all those research papers pointing to game-changing technology won't just disappear overnight.
I invested due to Texrad and must admit Bleepa has taken me by surprise so happy to sit back and watch what happens next. Despite being underwater, I can sense some excitiement building up (Hazl) and feel much better than when we were sub 1p and almost sub 0.5p!

[sonie01] 02/9/2019 19:59

I agree PeteK, what has happened to the said FDA approval etc? Potentially with Bleepa they have a product which could turn the company around and banish the past to history. From my due diligence, each NHS trust negotiates it's own procurement. This product though, in my opinion, has the potential to achieve a 'blanket' contract from the NHS as GDPR effects all NHS trusts rather than individuals. There are in the region of 420,000 clinicians and doctors in the NHS. Now feedback have said they hope to sell at £10/user/month. This equates to an income of £4.2m/month which equates to £50.4 per annum, add on the £500k or so they currently achieve in sales gives us a figure of around £51m. The cost of sales will be minimal as it is a software product and all costs would have been absorbed at the development stage. There will be some ongoing costs such as tweaks required to the software. Let's say cost of sales incl all other costs such as wages and marketing run to 10% of sales so around £5m/year. This would give us a net pre-tax of £46m. The market normally gives SAAS providers a PE ratio of about 20 whereas the more conventional service industries are given a PE ratio of between 10-13. So let's assume the worst case and give it a PE ratio of 10, this would value the company at £460m pricing the shares at 88p (520m shares). Of course if I was head of NHS I wouldn't give them £10/user/month I'd negotiate downwards. How much discount are feedback prepared to give? I'm guessing and please comment if you have more experience but 50% discount is not uncommon in large wholesale sales of software. Still values the share at 44p. We need to identify potential external threats. Is this software patented? Could this product be copied? Is there any other product that may be coming out in future from a competitor? I ask this because any contract over the value of £50k must go out to tender. Furthermore, I believe because of Brexit, the NHS are only signing urgent contracts at the mo, as the structure of the contracts change after Brexit which should be 31st October

[ducatiman] 02/9/2019 19:46

Pete, takeout at some stage. If Bleepa takes off it is the probable outcome.

[bobd29] 02/9/2019 19:44

Hi Pete, I believe the original aim was always a buy-out but at what level is anyone’s guess and this was based upon TexRAD in the pre-Bleepa era. So assuming the major holders still have that view then at some stage expect an offer, but if Bleepa takes FDBK to profitability they may revise their target upwards. All to play for next 2-3years imo, dyor.

[petekand] 02/9/2019 19:13

We lth's do have a right to moan at times and the only thing keeping me sane in this investment is the fact the major holders keep adding to their already massive holdings.
I just can't figure it out but surely they know more than any of us put together about the long game.

[petekand] 02/9/2019 19:07

So, the share price was pretty much firmly rooted at around 0.60p - 0.70p and my main concern was the next placing would have decimated the price.
From that viewpoint, it's not bad they raised at double the price despite the share price rallying to 2p on the Bleepa news. However, the leak may have prevented the raise being at even higher levels.
I am still concerned at to what happened to the monies raised last time which were earmarked for Texrad?
In a nutshell though, I am willing to sweep this episode under the carpet if Bleepa gains traction as I am sure the share price will then react to far higher levels than today's price.

[ducatiman] 02/9/2019 18:51

LR2, I think hazl could be my ex wife, if not she is displaying similar traits!

[ducatiman] 02/9/2019 18:50

That could go on for some time Ged. Good news needed to take the trading higher.

[georgesorearse] 02/9/2019 18:17

Balances it out nicely at cop and nice tight spread, after dilution youd expect to see an overhang ... the 2 x tr1's today took a chunk out of that and showed the bods belief in Bleepa ... will be interesting to review this in acouple of weeks and again in 6 months.

[ged5] 02/9/2019 17:43

Close! 858K and 500K

[ducatiman] 02/9/2019 17:30

Ged, might see 1m at 1.35 to balance.

[ged5] 02/9/2019 15:59

1M trade. How many more as we get closer to the Expo?